Known targets — ChEMBL curated mechanism
ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3CHRM1CHRM2CHRM3CHRM4ESR1ESR2GABRA1GABRB1GABRG2GBA1HRH1HTR1DHTR2AOPRD1OPRK1OPRM1SLC6A2SLC6A3TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8rplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Cadaverine Tartrate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.43 |
| ▸ | ADRA1D known ✓ | P25100 | 1/20 | 0.42 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.42 |
| ▸ | ADRA1B known ✓ | P35368 | 1/20 | 0.42 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 7/20 | 0.46 |
| ▸ | DRD3 | P35462 | 6/20 | 0.46 |
| ▸ | DRD4 | P21917 | 5/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | HTR1A | P08908 | 4/20 | 0.43 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7268921 | 0.91 | DRD2 (0.51) | DRD2DRD3DRD4HTR1ACACNA1G | |
| Cadaverine Tartrate SCHEMBL9871896 | 0.86 | HTR1A (0.47) | DRD2DRD3DRD4CYP1A2HTR1A | |
| Cadaverine Tartrate SCHEMBL9870639 | 0.84 | PARP1 (0.46) | DRD2DRD3DRD4CYP1A2HTR1A | |
| Cadaverine Tartrate SCHEMBL9872027 | 0.83 | SIGMAR1 (0.51) | DRD2DRD3CYP1A2HTR1ACACNA1G | |
| Cadaverine Tartrate SCHEMBL9871618 | 0.82 | DRD2 (0.44) | DRD2DRD3DRD4CYP1A2HTR1A | |
| Cadaverine Tartrate SCHEMBL9871625 | 0.82 | DRD2 (0.44) | DRD2DRD3DRD4CYP1A2HTR1A | |
| Cadaverine Tartrate SCHEMBL9870596 | 0.80 | HTR1A (0.45) | DRD2DRD3DRD4CYP1A2HTR1A | |
| Cadaverine Tartrate SCHEMBL9872353 | 0.80 | MAPT (0.47) | DRD2DRD3DRD4CYP1A2HTR1A | |
| Hydrochloric Acid SCHEMBL9870939 | 0.78 | HTR2A (0.53) | DRD2DRD3DRD4CYP1A2HTR1A | |
| Cadaverine Tartrate SCHEMBL9871114 | 0.78 | HTR1A (0.49) | DRD2HTR1ACACNA1GHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5071864-A | Administering for high blood pressure and central nervous syst em disorders | BASF AKTIENGESELLSCHAFT (DE) | 1991-12-10 | — | — | US | disclosed |